Opinion|Videos|July 10, 2024
Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
The colorectal cancer experts offer insights on a patient case and investigate the obstacles faced by patients with metastatic colorectal cancer requiring third-line or later therapy.
Advertisement
Episodes in this series
- Dr Marshall to Panel: Briefly provide comments and perspectives on this patient case.
- Dr Marshall to Dr Ciombor: What present challenges exist for patients with mCRC requiring 3L+ therapy?
- With evolving data and latest approvals, have we gotten closer to addressing those challenges and if so, how?
Advertisement
Related to this article
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
The FDA has approved zanidatamab plus chemotherapy with/without tislelizumab in frontline HER2-positive GEA based on data from HERIZON-GEA-01.
The oral pan-RAS molecular glue ERAS-0015 has received FDA fast track designation for the management of metastatic pancreatic adenocarcinoma.
The FDA set a target action date of February 2027 for the dostarlimab-gxly sBLA in dMMR/MSI-H locally advanced rectal cancer.
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5